Search results
Results from the WOW.Com Content Network
A 14-day course of "quadruple therapy" with a proton pump inhibitor, bismuth, tetracycline, and metronidazole or tinidazole is a more complicated but also more effective regimen. In a 2011 randomized, controlled trial, the per protocol eradication rates were 93% with quadruple therapy and 70% with triple therapy.
Triple therapy may refer to : . a first line therapy in Helicobacter pylori eradication protocols; any of the three drug treatments used in Management of HIV/AIDS; the combination of methotrexate, sulfasalazine, and hydroxychloroquine used to treat rheumatoid arthritis
Lansoprazole is used for treatment of: [3] Ulcers of the stomach and duodenum, and NSAID-induced ulcers; Helicobacter pylori infection, alongside antibiotics (adjunctive treatment), treatment to kill H. pylori causing ulcers or other problems involves using two other drugs besides lansoprazole known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole ...
The dual therapy of using vonoprazan with amoxicillin has been investigated for the treatment of H. pylori infection [6] and also compared with the triple therapy of using vonoprazan, amoxicillin, and clarithromycin for the eradication of H. pylori infection. [7] Both treatments have been found to be effective.
Antiretroviral drugs are used to manage HIV/AIDS.Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden.. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
TAP Pharmaceuticals was formed in 1977 as a joint venture between the two global pharmaceutical companies, Abbott Laboratories and Takeda Pharmaceutical Co. and was dissolved in 2008; its two most lucrative products were proton-pump inhibitor lansoprazole (Prevacid) and the prostate cancer drug, leuprorelin (Lupron). [1]
A combination of two types of therapeutic agents selectively killed breast cancer cells in a clinical trial, offering hope for a new treatment for triple-negative breast cancer.
The cost of telaprevir-based triple therapy for hepatitis C is $189,000 per sustained viral response. [11] On August 12, 2014, Vertex Pharmaceuticals announced that it would discontinue production of its brand of telaprevir, Incivek, due to falling demand for the drug caused by competition from newer hepatitis C treatments. [12]